9 Androgen receptors

Gary Berkovitz, Terry R. Brown, Claude J. Migeon

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Testosterone and its active metabolite dihydrotestosterone exert their influence on target cells through a specific intracellular protein receptor. Structural abnormalities of this receptor lead to a diminished androgen action within the cell and result in the syndrome of androgen insensitivity. Androgen insensitivity is classified on the basis of whether the insensitivity is complete or partial and whether the androgen receptor is normally present (AR( + )), absent (AR(-)) or diminished (AR(±)). All patients with androgen insensitivity have normal or high plasma levels of testosterone and elevated serum LH. Patients with complete androgen insensitivity are phenotypically female. The clinical presentation of partial androgen insensitivity is variable, ranging from a minimal amount of virilization to a completely masculine appearance. All patients described with a syndrome of androgen insensitivity are infertile. The influence of androgen receptor function in the pathogenesis of benign prostatic hypertrophy is being investigated. Androgen receptor content is also being studied as a possible marker of responsiveness to hormonal therapy in prostatic carcinoma.

Original languageEnglish
Pages (from-to)155-173
Number of pages19
JournalClinics in Endocrinology and Metabolism
Volume12
Issue number1
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Androgen Receptors
Androgen-Insensitivity Syndrome
Androgens
Testosterone
Virilism
Dihydrotestosterone
Prostatic Hyperplasia
Carcinoma
Metabolites
Serum
Proteins
Plasmas
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

9 Androgen receptors. / Berkovitz, Gary; Brown, Terry R.; Migeon, Claude J.

In: Clinics in Endocrinology and Metabolism, Vol. 12, No. 1, 01.01.1983, p. 155-173.

Research output: Contribution to journalArticle

Berkovitz, Gary ; Brown, Terry R. ; Migeon, Claude J. / 9 Androgen receptors. In: Clinics in Endocrinology and Metabolism. 1983 ; Vol. 12, No. 1. pp. 155-173.
@article{3e9dd415e0cd40eea2dad1f1452316ec,
title = "9 Androgen receptors",
abstract = "Testosterone and its active metabolite dihydrotestosterone exert their influence on target cells through a specific intracellular protein receptor. Structural abnormalities of this receptor lead to a diminished androgen action within the cell and result in the syndrome of androgen insensitivity. Androgen insensitivity is classified on the basis of whether the insensitivity is complete or partial and whether the androgen receptor is normally present (AR( + )), absent (AR(-)) or diminished (AR(±)). All patients with androgen insensitivity have normal or high plasma levels of testosterone and elevated serum LH. Patients with complete androgen insensitivity are phenotypically female. The clinical presentation of partial androgen insensitivity is variable, ranging from a minimal amount of virilization to a completely masculine appearance. All patients described with a syndrome of androgen insensitivity are infertile. The influence of androgen receptor function in the pathogenesis of benign prostatic hypertrophy is being investigated. Androgen receptor content is also being studied as a possible marker of responsiveness to hormonal therapy in prostatic carcinoma.",
author = "Gary Berkovitz and Brown, {Terry R.} and Migeon, {Claude J.}",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/S0300-595X(83)80034-6",
language = "English",
volume = "12",
pages = "155--173",
journal = "Clinics in Endocrinology and Metabolism",
issn = "0300-595X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - 9 Androgen receptors

AU - Berkovitz, Gary

AU - Brown, Terry R.

AU - Migeon, Claude J.

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Testosterone and its active metabolite dihydrotestosterone exert their influence on target cells through a specific intracellular protein receptor. Structural abnormalities of this receptor lead to a diminished androgen action within the cell and result in the syndrome of androgen insensitivity. Androgen insensitivity is classified on the basis of whether the insensitivity is complete or partial and whether the androgen receptor is normally present (AR( + )), absent (AR(-)) or diminished (AR(±)). All patients with androgen insensitivity have normal or high plasma levels of testosterone and elevated serum LH. Patients with complete androgen insensitivity are phenotypically female. The clinical presentation of partial androgen insensitivity is variable, ranging from a minimal amount of virilization to a completely masculine appearance. All patients described with a syndrome of androgen insensitivity are infertile. The influence of androgen receptor function in the pathogenesis of benign prostatic hypertrophy is being investigated. Androgen receptor content is also being studied as a possible marker of responsiveness to hormonal therapy in prostatic carcinoma.

AB - Testosterone and its active metabolite dihydrotestosterone exert their influence on target cells through a specific intracellular protein receptor. Structural abnormalities of this receptor lead to a diminished androgen action within the cell and result in the syndrome of androgen insensitivity. Androgen insensitivity is classified on the basis of whether the insensitivity is complete or partial and whether the androgen receptor is normally present (AR( + )), absent (AR(-)) or diminished (AR(±)). All patients with androgen insensitivity have normal or high plasma levels of testosterone and elevated serum LH. Patients with complete androgen insensitivity are phenotypically female. The clinical presentation of partial androgen insensitivity is variable, ranging from a minimal amount of virilization to a completely masculine appearance. All patients described with a syndrome of androgen insensitivity are infertile. The influence of androgen receptor function in the pathogenesis of benign prostatic hypertrophy is being investigated. Androgen receptor content is also being studied as a possible marker of responsiveness to hormonal therapy in prostatic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0020961818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020961818&partnerID=8YFLogxK

U2 - 10.1016/S0300-595X(83)80034-6

DO - 10.1016/S0300-595X(83)80034-6

M3 - Article

VL - 12

SP - 155

EP - 173

JO - Clinics in Endocrinology and Metabolism

JF - Clinics in Endocrinology and Metabolism

SN - 0300-595X

IS - 1

ER -